Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.
Tang X, Thompson KJ, Kalari KR, Sinnwell JP, Suman VJ, Vedell PT, McLaughlin SA, Northfelt DW, Aspitia AM, Gray RJ, Carter JM, Weinshilboum R, Wang L, Boughey JC, Goetz MP. Tang X, et al. Among authors: suman vj. Breast Cancer Res. 2023 May 24;25(1):57. doi: 10.1186/s13058-023-01656-x. Breast Cancer Res. 2023. PMID: 37226243 Free PMC article.
Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA. Ingle JN, et al. Among authors: suman vj. Breast Cancer Res Treat. 2006 Jul;98(2):217-22. doi: 10.1007/s10549-005-9152-1. Epub 2006 Mar 15. Breast Cancer Res Treat. 2006. PMID: 16538529 Clinical Trial.
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, Lingle WL, Erlander M, Ma XJ, Sgroi DC, Perez EA, Couch FJ. Goetz MP, et al. Among authors: suman vj. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2080-7. doi: 10.1158/1078-0432.CCR-05-1263. Clin Cancer Res. 2006. PMID: 16609019 Clinical Trial.
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. Goetz MP, et al. Among authors: suman vj. Breast Cancer Res Treat. 2007 Jan;101(1):113-21. doi: 10.1007/s10549-006-9428-0. Epub 2006 Nov 18. Breast Cancer Res Treat. 2007. PMID: 17115111
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN. Goetz MP, et al. Among authors: suman vj. Clin Cancer Res. 2008 Sep 15;14(18):5864-8. doi: 10.1158/1078-0432.CCR-08-0619. Clin Cancer Res. 2008. PMID: 18794098 Free PMC article.
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN. Wang L, et al. Among authors: suman vj. Cancer Res. 2010 Jan 1;70(1):319-28. doi: 10.1158/0008-5472.CAN-09-3224. Cancer Res. 2010. PMID: 20048079 Free PMC article.
245 results